ABSTRACT
Temporal and concentration dependences of the effect of the new synthetic gestagen 17alpha-acetoxy-3beta-butanoyloxy-6-methyl-pregna-4,6-dien-20-one (ABMP) and reference glucocorticoids (dexamethasone and hydrocortisone) and progesterone on the proliferative activity of rat skin fibroblasts were examined using the MTT assay. The results demonstrated that ABMP along with glucocorticoids produced an antiproliferative action against fibroblasts, with the maximum (38%) suppression of the metabolic activity of cells observed after 5-day incubation at a drug concentration of 10(-5) M.
Subject(s)
Cell Proliferation/drug effects , Fibroblasts/metabolism , Glucocorticoids/pharmacology , Progestins/pharmacology , Skin/metabolism , Animals , Dose-Response Relationship, Drug , Fibroblasts/cytology , Rats , Skin/cytologyABSTRACT
The effects of a new synthetic gestagen 17alpha-acetoxy-3beta-butanoyloxy-6-methyl-pregna-4,6-dien-20-on (ABMP) and reference drug progesterone on rat skin fibroblasts were evaluated by variations in lysosomal enzyme activity (cathepsin D and beta-glucosidase). Our results suggest that ABMP exhibits lysosomotropic properties, which depended on its concentration and time of treatment. The direct effect of progesterone on lysosomal enzyme activity in skin fibroblasts was compared to the influence of systemic treatment with gestagens on skin lysosomes. The data indicate that local application of gestagen preparations holds much promise for the therapy of skin diseases accompanied by increased proliferation (e.g. psoriasis).
